Rigel Pharmaceuticals, Inc.
(NASDAQ : RIGL)

( )
RIGL PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.11%62.180.0%$1999.69m
REGNRegeneron Pharmaceuticals, Inc. -2.18%599.472.5%$1212.04m
GILDGilead Sciences, Inc. -3.43%75.161.0%$972.03m
NVAXNovavax, Inc. 14.73%52.82102.0%$711.68m
AMGNAmgen, Inc. -1.22%226.911.3%$619.06m
VRTXVertex Pharmaceuticals, Inc. -0.46%286.641.9%$592.02m
BIIBBiogen, Inc. -1.84%301.451.6%$385.60m
ILMNIllumina, Inc. 0.65%365.413.5%$384.25m
SRNESorrento Therapeutics, Inc. -0.99%5.001.8%$320.03m
ALXNAlexion Pharmaceuticals, Inc. -0.82%118.922.0%$296.17m
SGENSeattle Genetics, Inc. 1.15%159.026.1%$258.80m
AAgilent Technologies, Inc. 2.01%89.911.6%$212.68m
BMRNBioMarin Pharmaceutical, Inc. 0.79%107.394.3%$185.56m
MGNXMacroGenics, Inc. 9.67%21.106.2%$174.18m
INCYIncyte Corp. -0.16%101.752.5%$166.58m

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.